Delivery Order SPE2DB22D3401-SPE2DB25FT5DA
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $4,684.70 to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) on June 4, 2025, with completion scheduled for June 5, 2025. The contract employs firm fixed pricing with no set-aside designation, indicating open competitive award. AmerisourceBergen, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, serves as a critical vendor for federal medical procurement and this delivery...
- The Defense Logistics Agency (DLA) awarded AmerisourceBergen Drug Corp a delivery order valued at $14,136.53 for RINVOQ ER 15 mg tablets (30-count units) on July 29, 2025, with an ultimate completion date of July 30, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and will be performed at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The delivery order represents a single transaction under AmerisourceBergen's broader...
- The Defense Logistics Agency awarded a $11,410.74 firm fixed price delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 15 MG tablets (30-count units) on August 8, 2025, with an ultimate completion date of August 11, 2025. This non-set-aside contract represents a pediatric delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The award was made competitively and is...
- The Defense Logistics Agency awarded a $19,152.04 firm fixed-price delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 15 MG tablets (30-count unit of use packaging). The contract was competitively awarded without set-aside designation and is scheduled for completion by August 4, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical distributor for federal medical procurement, particularly supporting military and veteran healthcare...
- The Defense Logistics Agency awarded a delivery order valued at $32,555.23 to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) on August 26, 2025, with an ultimate completion date of August 27, 2025. This competitively awarded, non-set-aside delivery order utilizes firm fixed pricing and represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract vehicle with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026....
- The Defense Logistics Agency awarded a $51,202.00 delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count units) on July 17, 2025, with an ultimate completion date of July 18, 2025. This competitively awarded, firm fixed-price contract represents a child delivery order under AmerisourceBergen's larger pharmaceutical supply vehicle with DLA. The contract carries no set-aside designation and will be performed at the vendor's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a $12,446.60 firm fixed-price delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 30 mg tablets (30-count units) on June 18, 2025, with an ultimate completion date of June 20, 2025. This non-set-aside contract represents a small-value pharmaceutical procurement fulfilling federal medical supply requirements. The award was made to AmerisourceBergen's Corporate Office division, located in Conshohocken, Pennsylvania, which serves as the company's primary...
- The Defense Logistics Agency awarded a $57,120.37 firm fixed-price delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 30 mg tablets (30-count units) on September 9, 2025, with an ultimate completion date of September 10, 2025. This non-set-aside contract was performed at the awardee's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical,...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $21,375.83 for RINVOQ ER 15 mg tablets (30-count units) on August 28, 2025, with an ultimate completion date of August 29, 2025. This competitively awarded, firm fixed-price contract is non-set-aside and represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. The pharmaceutical distributor, headquartered in Conshohocken, Pennsylvania,...
- The Defense Logistics Agency awarded a delivery order valued at $10,772.76 to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-unit package) on July 25, 2025, with completion expected by July 28, 2025. This competitively awarded, firm fixed-price delivery order represents a procurement of pharmaceutical inventory supporting military healthcare operations. The contract carries no set-aside designation and is being performed at AmerisourceBergen's corporate office location in...
- SPE2DB22D3401Indefinite Delivery Contract
- SPE2DB22D3401-SPE2DB25FT5DADelivery Order
The Defense Logistics Agency awarded a $3,111.66 firm fixed-price delivery order to AmerisourceBergen Drug Corp for RINVOQ ER 15 mg tablets (30-count) on July 14, 2025, with completion due July 15, 2025. This non-set-aside award represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving as a critical vendor for federal military and veteran healthcare systems. This delivery order falls within AmerisourceBergen's comprehensive pharmaceutical supply agreement with DLA, which enables the company to distribute a broad range of medications, vaccines, and medical supplies across multiple therapeutic domains to support military healthcare programs worldwide. The contract vehicle serves customers including the Defense Health Agency and U.S. Coast Guard, demonstrating the company's capability to meet federal procurement requirements through open competition and its established role as a prime pharmaceutical vendor for Department of Defense medical supply operations.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.1k | 7/14/25 |